newsfilter
← Earnings
Earnings Releases·

PTC Therapeutics — Third Quarter 2026 Earnings Summary

  • Total revenue surged to $358 million in Q3 2026 from $211.0 million in Q3 2025, driven by a 100%+ increase in net product revenue to $275.9 million, while Sephience revenue grew 20% sequentially to $181.9 million.
  • Full-year 2026 total revenue guidance was raised to $1.29–$1.32 billion (from $1.20–$1.30 billion implied by prior ranges), with product revenue guidance increased to $960–$990 million, and management expects to achieve cash flow breakeven in 2026.
  • The company acquired ST-920 Fabry disease gene therapy for $111.0 million upfront, with a BLA submission expected in Q4 2026 and a potential commercial launch in 2027, alongside advancing Votoplam and Vatiquinone programs.
  • Net loss widened to $51.7 million in Q3 2026 compared to $15.9 million net income in Q3 2025, primarily due to $111.0 million in acquired in-process research and development expenses, while cash and marketable securities rose to $2.13 billion.
Company
PTC THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology